A recent federal court ruling has vacated HRSA’s long-standing 2013 GPO policy, raising new questions about how 340B hospitals can approach initial drug inventory purchases. While the decision may reduce WAC exposure, it does not remove the statutory GPO prohibition or the compliance risks tied to it.
In this episode, Katy Lees breaks down what the ruling actually changes, where operational realities remain the same, and how health systems should think about inventory strategy, replenishment models, and audit risk in the absence of clear HRSA guidance. This discussion is especially relevant for compliance leaders, pharmacy teams, and executives responsible for governance and financial oversight.
Katy brings a structured, practical lens to a complex regulatory shift, helping organizations separate signal from noise and make defensible decisions in a rapidly evolving environment. Watch Now >
